All In MedTech

Device Trial Radar · NCT03247023

Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

65

Actual

Start

Sep 18, 2017

Primary completion

Sep 6, 2023

Study completion Sep 6, 2023

Sponsor

Lead sponsor
Smith & Nephew, Inc.Public (SNN)
Sponsor type
Industry
Collaborators
Smith & Nephew Orthopaedics AG
First posted
Aug 11, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)

Conditions

  • Degenerative Arthritis
  • Rheumatoid Arthritis
  • Traumatic Arthritis

Interventions

  • Implantation of Integra Cadence Total Ankle SystemDevice

    Primary Ankle Arthroplasty

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Implant Survivorship at 2 YearsTime frame: 2 years

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Foot and Ankle Institute

    Woluwe-St-Lambert, Belgium

  • St. Michael's Hospital

    Toronto, Canada

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.